Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Recurrence 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Cyclophosphamide 33fludarabine phosphate 19Peripheral Blood Stem Cell Transplantation 19Mycophenolic Acid 17Whole-Body Irradiation 15Etoposide 15Rituximab 14Tacrolimus 13Busulfan 12Vincristine 11Prednisone 11Methotrexate 11Filgrastim 11Doxorubicin 11Cyclosporine 11Radiotherapy 10Brentuximab Vedotin 10Antilymphocyte Serum 10Methylprednisolone 8Cytarabine 8Melphalan 7Cisplatin 6Ifosfamide 5Gemcitabine 5merphos 4ibritumomab tiuxetan 4Sirolimus 4Flow Cytometry 4Dexamethasone 4Cyclosporins 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Large-Cell, Anaplastic × iratumumab × Clear all
NCT00298467 2010-04-26

MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

Bristol-Myers Squibb

Phase 2 Withdrawn
45 enrolled
DermatologicLymphoidSarcoma

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡